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Objective. Insulinomas are rare pancreatic tumours. Population-based data on their incidence, clinical picture, diagnosis, and
treatment are almost nonexistent. The aim of this study was to clarify these aspects in a nationwide cohort of insulinoma
patients diagnosed during three decades. Design and Methods. Retrospective analysis on all adult patients diagnosed with
insulinoma in Finland during 1980–2010. Results. Seventy-nine patients were diagnosed with insulinoma over the research
period. The median follow-up from diagnosis to last control visit was one (min 0, max 31) year. The incidence increased from
0.5/million/year in the 1980s to 0.9/million/year in the 2000s (p = 0 002). The median diagnostic delay was 13 months and did
not change over the study period. The mean age at diagnosis was 52 (SD 16) years. The overall imaging sensitivity improved
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from 39% in the 1980s to 98% in the 2000s (p < 0 001). Seventy-one (90%) of the patients underwent surgery with a curative aim,
two (3%) had palliative surgery, and 6 (8%) were inoperable. There were no signiﬁcant diﬀerences in the types of surgical
procedures between the 1980s, 1990s, and 2000s; tumour enucleations comprised 43% of the operations, distal pancreatic
resections 45%, and pancreaticoduodenectomies 12%, over the whole study period. Of the patients who underwent surgery with
a curative aim, 89% had a full recovery. Postoperative complications occurred in half of the patients, but postoperative mortality
was rare. Conclusions. The incidence of insulinomas has increased during the past three decades. Despite the improved
diagnostic options, diagnostic delay has remained unchanged. To shorten the delay, clinicians should be informed and alert to
consider the possibility of hypoglycemia and insulinoma, when symptomatic attacks are investigated in diﬀerent sectors of the
healthcare system. Developing the surgical treatment is another major target, in order to lower the overall complication rate,
without compromising the high cure rate of insulinomas.
1. Introduction
Insulinomas are the most common functioning endocrine
neoplasms of the pancreas with an estimated incidence of
1–4 permillion per year. Less than 10% are reported tometas-
tasize [1, 2]. During the past few decades, the incidence of all
neuroendocrine neoplasms (NENs) has increased rapidly
compared with the general incidence of cancers [3, 4]. The
increase may in part be explained by improved diagnostics,
including more sensitive imaging methods [4, 5]. Whether
the incidence of insulinomas has followed the increasing
trend of NENs in general is presently unknown.
In patients with insulinoma, episodes of hyperinsuline-
mic hypoglycemia cause various autonomic and neuroglyco-
penic symptoms, which usually emerge in the fasting state.
Documentation of the so-called Whipple’s triad, i.e., symp-
toms consistent with hypoglycemia, a low plasma glucose
measured at the time of the symptoms, and immediate relief
of the symptoms after administration of glucose, is the cor-
nerstone of insulinoma diagnostics [6–8]. Demonstration of
a low plasma glucose concomitant with inappropriately high
serum insulin and C-peptide levels in a symptomatic patient
constitutes the basis for the biochemical diagnosis, with the
exclusion of other causes of hyperinsulinemic hypoglycemia
[7]. β-Hydroxybutyrate levels of 2.7mmol/liter or less, an
increase in plasma glucose of at least 1.4mmol/liter after iv
glucagon, and a negative screen for oral hypoglycemic agents
distinguish endogenoushyperinsulinemichypoglycemia from
that caused by other mechanisms [7]. A 72-hour fasting test
with plasma glucose, insulin, and C-peptide measurements
is considered the gold standard for the biochemical diagnosis
of insulinoma [7]. Gadolinium-enhanced dynamic magnetic
resonance imaging (MRI), 3-phase computed tomography
(CT), and endoscopic ultrasonography (EUS) have been
regarded as the most useful imaging modalities for insuli-
noma evaluation [8]. In experienced hands, the sensitivity
of EUS is 70–95%, and combined with 3-phase CT, sensitiv-
ities up to 100% have been reported [8, 9]. Conventional US,
CT, and MRI are widely available and thus often applied as
the ﬁrst-line imaging methods, but their success rates remain
at 10–40% in many studies [9]. During the past 10 years,
new functional nuclear imaging methods (such as 18F-
DOPA-PET/CT, 68Ga-DOTA-NOC-PET/CT, and recently,
GLP-1-analogue-PET/CT) have also become available, and
promising results have been reported with sensitivities
exceeding 90% [10–13]. These functional imaging methods
have largely replaced the previously more commonly used
diagnostic angiography (based on detection of a hypervas-
cular lesion consistent with an insulinoma) and octreotide
scintigraphy, with general sensitivities of 60 and 50%,
respectively [9]. Laparoscopic surgery has developed, and
pancreas-preserving surgical methods have become more
common in many centers, to avoid the adverse eﬀects of
extensive pancreatic resections, such as exocrine dysfunc-
tion and insulin-dependent diabetes [14].
Because previous reports on single-center cohorts have
suggested changes in the clinical picture, diagnostics, and
treatment of insulinoma [10, 15–18], we wanted to clarify
these aspects in an unselected, nationwide cohort of patients
with insulinomas, diagnosed over a 3-decade period. More-
over, no previous population-based data exist on changes
in the incidence of insulinomas, although an increase in
the overall incidence of NENs has been noted worldwide.
We have previously reported a pilot study of 23 insulinoma
patients included in the present study, diagnosed at one
of the participating centers (Tampere University Hospital,
Finland) [19].
2. Subjects and Methods
2.1. Patient Population. A retrospective analysis was per-
formed on adult (≥18 years) patients diagnosed with an insu-
linoma in Finland during 1980–2010. To ﬁnd all the Finnish
insulinoma patients, a comprehensive search was carried out
in the patient record and pathology registries in all the ﬁve
university hospitals, as well as at the Finnish Cancer Registry.
In Finland, the diagnostics and treatment of insulinomas are
centralized in the University Hospitals. Diagnosis codes for
benign and malignant pancreatic tumours, as well as hypo-
glycemia, were searched for in the patient records of all the
ﬁve Finnish University Hospitals (detailed search strategy
in Supplementary Materials (available here)). To double-
check the search results of surgically managed insulinomas,
pathology registries of the University Hospitals were searched
for the term insulinoma∗. In addition, a search in the Finnish
Cancer Registry, a nationwide database on all cancers diag-
nosed in Finland, was performed with ICD-O-3 morpholog-
ical codes 8150 Pancreatic endocrine tumour and 8151
Insulinoma. The case histories of all the patients identiﬁed
by the searches described above were reviewed to verify if
the inclusion criteria of the present study were fulﬁlled.
2.2. Inclusion Criteria. The diagnosis of insulinoma was
based on documentation of the Whipple’s triad and/or
2 International Journal of Endocrinology
hyperinsulinemic hypoglycemia together with histopatho-
logical veriﬁcation of an insulinoma. Histopathology was
regarded as positive, if the diagnosis was pancreatic neuro-
endocrine tumour and insulin staining (if performed) was
positive. In patients without histopathological veriﬁcation,
the diagnosis required documentation of the Whipple’s triad
or hyperinsulinemic hypoglycemia, as well as imaging ﬁnd-
ings of a pancreatic tumour compatible with an insulinoma.
2.3. Data Collection. Data was collected on the clinical pic-
ture, laboratory ﬁndings, imaging, pathology, treatment,
and follow-up of insulinomas. The symptoms were classiﬁed
as neuroglycopenic and autonomic. Laboratory ﬁndings reg-
istered were the lowest incidental blood glucose concentra-
tion, measurements of glycated hemoglobin (HbA1c), and
the results of fasting tests and prolonged (5-hour) OGTTs.
The fasting tests were analysed according to the Endocrine
Society 2009 Guideline criteria for hyperinsulinemic hypo-
glycemia [7] (Table 1). The blood glucose values were multi-
plied by 1.15, to be comparable with the plasma glucose
measurements. Any medication potentially aﬀecting insulin
secretion or insulin sensitivity was documented. The number
and the size of insulinomas, the type of operation, surgical
complications, and the histopathological diagnosis were reg-
istered. Postoperative hospital mortality was recorded. Post-
operative surgical complications were classiﬁed according
to the Clavien-Dindo (CD) classiﬁcation [20, 21]. The inci-
dence of insulinoma was calculated according to the popula-
tion statistics provided by Statistics Finland [22].
The ethical committee of Tampere University Hospital
and the National Institute for Health and Welfare approved
the study protocol.
2.4. Statistical Analysis. The statistical analysis was con-
ducted with the IBM SPSS Statistics for Windows, Version
22.0 (IBM Corp., Armonk, NY, USA). The numerical results
are presented as mean (standard deviation, SD) for normally
distributed variables, median (minimum, maximum) for
other continuous variables, and number (%) for categorical
variables. Diagnostic delay was calculated from the ﬁrst pre-
sentation of hypoglycemic symptoms up to the clinical diag-
nosis of insulinoma, as documented in the patient records.
Diﬀerences were analysed between insulinomas diagnosed
in the 1980s, 1990s, and 2000s. Categorical variables were
analysed by the chi-square test or the Fisher exact test, as
appropriate. Numerical variables were assessed by the
Mann-Whitney U test, Student t-test, or Kruskal-Wallis test,
as appropriate. A two-sided p value below 0.05was considered
statistically signiﬁcant. The changes in the incidence of insu-
linomas were assessed with Poisson regression, conducted
with STATA Statistical Software: Release 13 (StataCorp LP,
College Station, TX, USA).
3. Results
3.1. Patient Characteristics and Incidence of Insulinomas.
Altogether, 79 insulinoma patients were identiﬁed, 55 (70%)
of them female. In 73 patients, the diagnosis was conﬁrmed
histopathologically, whereas in 6 patients, the diagnosis
was based on documentation of the Whipple’s triad or
hyperinsulinemic hypoglycemia and imaging ﬁndings com-
patible with an insulinoma. Of these 6 patients without his-
topathologic veriﬁcation, 4 were inoperable (2 malignant
insulinomas with distant metastases and 2 clinically classi-
ﬁed as benign but inoperable due to other diseases). One
patient with hypoglycemic symptoms, conﬁrmed hyperinsu-
linemic hypoglycemia, and imaging results consistent with
an insulinoma died of bleeding complicating the pancreatic
surgery, and histopathological veriﬁcation of the insulinoma
was not obtained. In one patient, diagnosed in the 1980s, no
insulinoma could be localized in the primary surgery,
despite the preoperative transhepatic portovenous sampling
(THPVS) ﬁndings compatible with an insulinoma located
in the body of the pancreas. As the hypoglycemic symptoms
progressed, a diagnostic angiography was performed to
localize the tumour. As a complication of this angiography,
lethal intraabdominal bleeding developed, and no histopath-
ological veriﬁcation of the tumour was obtained.
The median length of follow-up from the clinical diagno-
sis of insulinoma up to the last control visit at the University
Hospital was one (0, 31) year. MEN1 syndrome was diag-
nosed in two patients, both of them associated with a solitary
insulinoma. The mean age at the time of diagnosis was 52
(SD 16) years. The MEN1 patients were younger at the diag-
nosis (mean age 42 years in MEN1 vs. 52 years in sporadic
cases), but the diﬀerence was not statistically signiﬁcant
(p = 0 368). The median age at the time of diagnosis did not
diﬀer between malignant [55 (39, 76) years] and nonmalig-
nant (insulinomas classiﬁed as benign or undetermined)
insulinomas [51 (21, 84) years, p = 0 098]. The median BMI
at diagnosis was 27 (20, 51) kg/m2.
The incidence of insulinoma over the whole research
period was 0.6 per million adults per year and increased
remarkably during the study period (0.5, 0.4, and 0.9/mil-
lion/year in the 1980s, 1990s, and 2000s, respectively). In
Poisson regression analysis, the yearly incidence rate ratio
was 1.043, and the increase in incidence was statistically sig-
niﬁcant (p = 0 002). The increasing incidence of insulino-
mas is presented in Figure 1. The median diagnostic delay
was 13 months (17, 11, and 17 months in the 1980s,
1990s, and 2000s, respectively). Thirty-one of 79 patients
were ﬁrst examined for their symptoms by specialities other
than endocrinology, most often by neurology, neurosurgery,
or cardiology.
3.2. Symptoms. All but two patients had hypoglycemic
symptoms before the insulinoma diagnosis (Table 2). The
Table 1: The criteria for endogenous hyperinsulinemic hypoglycemia
according to the Endocrine Society Guideline 2009 [7].
Symptoms and signs, or both, consistent with hypoglycemia with
concomitant plasma concentrations of
Glucose <3.0mmol/l
Insulin ≥18 pmol/l
C-Peptide ≥0.2 nmol/l
Proinsulin ≥5.0 pmol/l
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symptoms were usually progressive, provoked by fasting, and
at worst, occurred daily or weekly. 96% of the patients had
neuroglycopenic symptoms, and 77% had autonomic symp-
toms. The most common presenting symptoms were confu-
sion (86%), drowsiness (58%), and excessive sweating (57%).
Weight gain was documented in 56% of the patients, of whom
one-third gained weight more than 10 kilograms.
Of the two patients without hypoglycemic symptoms
prior to the diagnosis of insulinoma, one was found in con-
nection with theMEN1-investigations of the patient’s sibling,
and the symptoms related to hypoglycemia ﬁrst appeared 3
years after the diagnosis. The other patient presented with
jaundice and diarrhea related to a pancreatic tumour. The
tumour was operated on, and hypoglycemic symptoms and
veriﬁed hyperinsulinemic hypoglycemia did not occur until
8 months after the primary operation, when liver metastases
were detected.
3.3. Laboratory Findings. In all except the two patients
described above, hypoglycemia had been detected, either
spontaneously or in a fasting test, prior to the insulinoma
diagnosis. The median lowest spontaneous plasma glucose
was 2.0 (1.3, 4.9) mmol/l (n = 62). The median glycated
hemoglobin (HbA1c) value at diagnosis was 4.9% (3.7, 5.7;
n = 31). Hyperinsulinemic hypoglycemia was veriﬁed in 65
(82%) of the patients, either spontaneously, during a fasting
test, or during a prolonged OGTT.
Sixty-ﬁve patients underwent a fasting test, aiming at a
24, 36, or 72-hour fasting time. Data for analysis was avail-
able on 64 patients. In the fasting test, the median plasma
glucose nadir was 2.2 (0.8, 4.5) mmol/l (n = 64), and the
corresponding serum insulin 16 (1.5, 154) mU/l (n = 55)
and C-peptide 0.9 (0.3, 4.4) nmol/l (n = 44). The criteria
for endogeneous hyperinsulinemic hypoglycemia by the
Endocrine Society [7] were met in 92% of the tests, after a
median fasting time of 14 (0, 36) hours. In 5 patients, the
criteria were not met, but in three of them, the test was
interrupted prematurely. Eleven (14%) patients underwent
a prolonged OGTT, and three of these tests veriﬁed hyper-
insulinemic hypoglycemia.
3.4. Imaging Methods. The tumour was localized preopera-
tively in 59 (75%) of the patients. In 9 (11%) of the patients,
the imaging results were indeﬁnite, and in 11 (14%) negative.
A median of 3 imaging modalities was used per patient (1, 7).
The most frequently used imaging modalities were CT scan,
angiography, MRI, EUS, and 18F-DOPA-PET/CT, of which
EUS, 18F-DOPA-PET/CT, and MRI were the most successful
ones, with overall sensitivities of 78, 55, and 50%, respec-
tively. A CT scan was performed on 90% of the patients,
and the sensitivity of CT scanning improved remarkably
under the study period, from 6% in the 1980s to 51% in the
2000s (p = 0 001). The overall imaging sensitivity improved
during the study period from 39% in the 1980s to 98% in
the 2000s (p < 0 001) (Table 3). EUS had the best sensitivity
(78%) for detecting small tumours (diameter of 1 cm or
less), while the sensitivities of other modalities were 43%
for 18F-DOPA-PET/CT, 40% for MRI, 33% for octreotide
scintigraphy, 23% for CT, and 0% for transabdominal US.
Intraoperative US was performed in 19 patients, with an
overall success rate of 79%.
3.5. Medical Treatment. Fifty-ﬁve (70%) of the patients used
preoperative medication: 47 (59%) used diazoxide, 10 (13%)
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Figure 1: The incidence of insulinomas in Finland 1980–2010. In Poisson regression analysis, the yearly incidence rate ratio was 1.043, and
the increase in incidence was statistically signiﬁcant (p = 0 002).
Table 2: The presenting symptoms of the 79 patients diagnosed
with an insulinoma in Finland 1980–2010.
Symptom n %
Autonomic symptoms 61 77
Sweating/diaphoresis 45 57
Tremor 21 27
Anxiety, aggressiveness 16 20
Palpitations 14 18
Neuroglycopenic symptoms 76 96
Confusion 68 86
Drowsiness 46 58
Visual disturbances 41 52
Amnesia 35 44
Unconsciousness 36 46
Lightheadedness 26 33
Hunger 24 30
Paresthesias 20 25
Headache 16 20
Seizures 15 19
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used a somatostatin analogue, and 4 (5%) used both com-
pounds. The median maintenance dose of diazoxide was
150 (25, 600) mg/day, and a favorable response (relief of
symptoms and/or improvement of plasma glucose levels) to
diazoxide was documented in 19 (63%) of the 30 patients
with data available.
3.6. Surgery. Seventy-one of the 79 (90%) patients underwent
pancreatic surgery with a curative aim, two (3%) had pallia-
tive surgery of the primary tumour, and six cases (8%) were
inoperable. The operations included 31 enucleations (43%),
33 distal resections (45%), and 9 pancreticoduodenectomies
(PDs; 12%). In one of the two patients with palliative pancre-
atic surgery, also liver resections were performed, to reduce
the tumour load.
The median tumour diameter for enucleations tended to
be smaller [10 (5, 28) mm] than for distal resections [15 (7,
60) mm] or PDs [15 (5, 26) mm], (p = 0 073). Enucleations
became slightly more common during the study period, but
there was no statistically signiﬁcant diﬀerence in the distribu-
tion of surgical procedures between the 1980s, 1990s, and
2000s in the whole cohort (Table 4, p = 0 355). In Helsinki
University Hospital, where most of the insulinoma opera-
tions were performed, the enucleation rate increased from 0
in the 1980s to 44% in the 2000s, and the distal resection rate
decreased from 100 to 56%, respectively (p = 0 021).
Postoperative hospital mortality was 3% (2/73). Postop-
erative complications, graded according to the Clavien-
Dindo classiﬁcation [20, 21], occurred in 51% of the patients
(Figure 2); CD grade I in 3% and signiﬁcant CD grades II–IV
complications in 45%. The most common postoperative
complications were pancreatic ﬁstula (19%), pancreatitis
(10%), intra-abdominal abscess (14%), and wound infection
(10%). Pancreatic ﬁstulas occurred in 19% of the patients
(23% after tumour enucleations, 12% after distal resections,
and 33% after PDs, without a signiﬁcant diﬀerence between
the surgical methods (ns; p = 0 293)). Overall major compli-
cations (CD grades III–V) occurred in 16% of enucleations,
24% of distal resections, and 56% of PDs (p = 0 062). There
was no diﬀerence in the Clavien-Dindo grade between the
1980s, 1990s, and 2000s (p = 0 894), between the surgical
centers (p = 0 079) or between the insulinomas classiﬁed as
malignant and those classiﬁed as nonmalignant (p = 0 488).
The postoperative mortality for insulinoma enucleation was
3%, for distal resection 3%, and for PD 0% (p = 1 00). Two
patients died during the postoperative hospitalization, both
because of surgical complications. One patient with a single
insulinoma located in the pancreatic tail died because of
bleeding during tail resection. One patient died during a
reoperation because of a pancreatic ﬁstula, severe pancreati-
tis, and sepsis after primary enucleation of a benign insuli-
noma in the head of the pancreas.
Table 3: The imaging methods used and their sensitivities in the localization of insulinomas in Finland 1980–2010.
Localizing method
1980–1989 (n = 18) 1990–1999 (n = 18) 2000–2010 (n = 43)
Ratioa % Ratio % Ratio %
Abdominal US 1/12 8 1/12 8 4/11 36
Angiography 3/14 21 3/9 33 7/11 64
CT scan 1/17 6 3/17 17 19/37 51
EUS NA 4/6 67 14/17 82
ERCP 0 0 0/2 0 NA
MRCP NA NA 1/1 100
MRI NA 2/6 33 12/22 55
Octreotide scintigraphy NA 2/6 33 1/9 11
THPVS 3/4 75 NA NA
18F-DOPA-PET/CT NA 0/1 0 11/19 58
18F-FDG-PET/CT NA NA 0/1 0
Overall detection 7/18 39 10/18 56 42/43 98
aRatio indicates the proportion of patients in whom the imaging method was successful in localizing the insulinoma. US indicates ultrasonography; CT:
computed tomography; EUS: endoscopic ultrasonography; ERCP: endoscopic retrograde cholangiopancreatography; MRCP: magnetic resonance
cholangiopancreatography; MRI: magnetic resonance imaging; THPVS: transhepatic portovenous sampling; 18F-DOPA-PET: 18F-dihydroxyphenylalanine
positron emission tomography; 18F-FDG-PET: 18F-ﬂuorodeoxyglucose positron emission tomography; NA: not applicable.
Table 4: Surgical treatment of insulinoma patients in Finland 1980–2010.
Surgical procedure
1980–1989
(n = 13)
1990–1999
(n = 19)
2000–2010
(n = 41) Total (n = 73)
n % n % n % n %
Tumour enucleation 4 31 11 58 16 39 31 43
Distal resection 8 61 5 26 20 49 33 45
Pancreaticoduodenectomy 1 8 3 16 5 12 9 12
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3.7. Tumour Characteristics. Seventy-three of the 79 patients
had a solitary insulinoma, and 5 had multiple tumours (data
not available for one patient). In 44% of the patients, the
tumour was located in the head of the pancreas, while
tumours in the pancreatic tail and body accounted for 27%
and 18%, respectively. In 8 patients, the localization of the
insulinoma was not documented. The median tumour diam-
eter was 14 (5, 60) mm.
In the patient record and pathology registry data, the
insulinomas were classiﬁed as benign in 58 (73%), malignant
in 11 (14%), and undetermined in 6 (8%) patients, using the
contemporary classiﬁcations of PNENs. Distant metastases
were documented in 9 (11%) patients. In the two patients
without distant metastases, the malignant classiﬁcation
was based on a locally invasive growth of the tumour and
a relatively high Ki-67 labeling index (9%). Insulin staining
was performed in 59 specimens and was positive in all of
them. The tumours were also stained positively with other
neuroendocrine markers, e.g., chromogranin A (39 positive/
42 tested) and synaptophysin (32/35). Ki-67/MIB-1 staining
was performed in 29 specimens and was ≤2% in 20 (69%)
and ≥5% in 7 (24%) of the tested specimens (min< 1%,
max 50%).
3.8. Management and Outcome of Insulinomas Classiﬁed as
Benign or Undetermined. The median length of follow-up
of insulinomas classiﬁed as benign was 0.7 (0.1, 26) years
and 1.6 (0.2, 31) years for those classiﬁed as undetermined.
A total of 66 of the 68 patients with nonmalignant insulino-
mas underwent surgery, and 62 of them had a full recovery.
Two patients, as described above, died of surgical complica-
tions and one of complications in a diagnostic angiography.
In one patient, tumour recurrence was detected 10 years after
the primary enucleation of a single benign tumour, located in
the head of the pancreas. This patient was treated with
somatostatin analogues and a reoperation, and no recurrence
was detected during 7.5 years of follow-up after the reopera-
tion. Two patients with benign insulinomas were inoperable
Tumour enucleation Partial resection Pancreaticoduodenectomy
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Figure 2: Postoperative overall complications graded according to the Clavien-Dindo classiﬁcation [20, 21] in the 73 insulinoma patients
operated in Finland 1980–2010. aComplication grade (0–V) according to the Clavien-Dindo classiﬁcation, where 0 indicates no
complications and V indicates death of the patient. There was no statistically signiﬁcant diﬀerence in the Clavien-Dindo grades between
the surgical methods (p = 0 218, Fisher exact test).
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due to other diseases: one of them was treated with diazoxide,
and the symptoms did not progress during the 6-year follow-
up. The other patient was treated by frequent meals only,
during 13 years of follow-up.
3.9. Management and Outcome of Insulinomas Classiﬁed as
Malignant. The median length of follow-up of the insulino-
mas classiﬁed as malignant was 3 (1, 27) years. Of the 11
patients with a malignant insulinoma, 5 underwent surgery
with a curative aim. Two of them had immediate disease pro-
gression due to distant metastases (liver and lung, liver and
jejunal mesentery): one of them was treated with a somato-
statin analogue and the other one with diazoxide, predniso-
lone, and streptozotocin. Two patients had relapses, 1 year
and 5 years after the primary surgery. The ﬁrst one was oper-
ated on the liver metastases, as well as treated with diazoxide,
somatostatin analogues, 5-ﬂuorouracil-streptozotocin, epiru-
bicin, and interferon alpha, and the other one was treated
with diazoxide, low-dose interferon, and chemoembolization
of the liver metastases. One of the insulinomas classiﬁed as
malignant was cured by surgery. This insulinoma had no dis-
tant metastases, but the histopathologic diagnosis of malig-
nancy was based on the local invasion and the relatively
high Ki-67 index (9%) of the tumour.
In two patients with malignant insulinoma, distal pancre-
atic resections were performed as palliative surgery. In both of
them, the disease progressed, and the patients died 1.3 years
and 4.2 years after surgery. Of the four inoperable malignant
insulinomas, all progressed. Medical treatment of these inop-
erable patients and the patients with palliative surgery
included diazoxide (n = 4), somatostatin analogues (n = 5),
radiation therapy of metastases (n = 2), 5-ﬂuorouracil-
streptozotocin (n = 3), sunitinib (n = 1), doxorubicin (n = 1),
doxorubicin-dacarbazine (n = 1), interferon alpha (n = 3),
peroral corticosteroids (n = 4), dearterialization and emboli-
zation of liver arteries (n = 1), chemoembolization of liver
metastases (n = 1), resection and thermoablation of liver
metastases (n = 1), and superselective embolization of a
branch of the gastroduodenal artery (n = 1).
4. Discussion
In this study, we demonstrate an almost two-fold increase in
the incidence of insulinomas in Finland, from 0.5/million/
year in the 1980s and 0.4/million/year in the 1990s to 0.9/
million/year in the 2000s. In spite of the improved diagnostic
methods available, the delay from the ﬁrst symptoms to the
diagnosis has remained unchanged over the last three
decades (median delay ca. 13 months). Preoperative imaging
has improved remarkably, and in the 2000s, all the insulino-
mas except for one were localized preoperatively. Eighty-nine
percent of the patients who underwent surgery with a cura-
tive aim had a full recovery, but postoperative complications
occurred in half of the patients.
The observed incidence of 0.4–0.9/million adults/year is
slightly lower than the estimated incidence of 1–4/million/
year suggested in earlier studies [1, 2]. Earlier estimates of
the incidence of insulinoma might be incorrectly high
because of the selected data of single-center cohorts or data
from a limited area. For example, in the large Mayo Clinic
study of 224 insulinoma patients treated between 1927
and 1986, the incidence of insulinoma was calculated
based on eight detected insulinomas among the residents
of Olmsted County [2]. In our study, the incidence of insuli-
noma increased approximately two-fold during the study
period, being 0.9/million adults/year in the 2000s. This may
be explained by improved diagnostic methods, especially
imaging. An actual increase in the incidence of insulinomas,
however, cannot be excluded.
In this cohort, all except two patients had symptomatic
hypoglycemia before the diagnosis of insulinoma; in the
remaining two patients, the symptoms emerged only after
the diagnosis. The median duration of hypoglycemic symp-
toms before the diagnosis was 13 months, which is slightly
shorter than the 18 months reported in previous studies
[2, 16]. Thirty-one (39%) of the patients were ﬁrst examined
by other specialities, reﬂecting the diverse symptoms associ-
ated with insulinomas. The episodic symptoms were often
interpreted as cerebrovascular disorders, epilepsy, or psychi-
atric disorders.
In the present cohort, the criteria for hyperinsulinemic
hypoglycemia were met in 91% of the fasting tests, and all
the positive ﬁndings were detected within a 36-hour fast.
Our results support the suggestion that the diagnosis of
endogeneoushyperinsulinemichypoglycemia canbeachieved
in over 90% of cases within 48 hours, and a 48-hour fast could
replace the current 72-hour fast as the diagnostic standard
[23]. According to a Mayo clinic study, 20% of insulinoma
patients have additionally and 6% exclusively postprandial
symptoms [24]. In patients with postprandial symptoms
only, the corresponding plasma measurements can be per-
formed postprandially or during a prolonged oral glucose
tolerance test (OGTT) [1, 7, 25]. In the present cohort, post-
prandial symptoms were documented in 6 (8%) patients, but
all of them had also symptoms provoked by fasting.
In the preoperative localization of insulinomas, noninva-
sive imaging methods, primarily CT and MRI, are preferred.
The lower sensitivity and limited utility in providing addi-
tional information have reduced the use of transabdominal
US as a diagnostic modality [14]. Invasive localizingmethods,
including selective angiography, EUS, and selective arterial
calcium stimulation (SACS) test, are applied when the nonin-
vasive studies fail to localize an insulinoma. Blind pancreatic
resection is not recommended because of a low cure rate and
a high risk of complications [26]. In this study cohort, all the
aforementioned localizing methods were applied, except for
the SACS test, which has also proved to be a sensitive method
for localizing insulinoma [27]. During the study period, the
preoperative localization of insulinomas improved remark-
ably, and in the 2000s, up to 98% of the tumours were local-
ized preoperatively. In the 2000s, the most sensitive imaging
methods were EUS (sensitivity 82%), selective angiography
(64%), 18F-DOPA-PET/CT (58%), MRI (55%), and CT
(51%), in accordance with the sensitivities reported in a
recent systematic review [14]. 68Ga-NOTA-Exendin-4 PET/
CT, a novel technique for localizing insulinomas with a
reported sensitivity of 97%, was not available during the
study period [28].
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Most patients underwent surgery with a curative aim, and
3%had palliative surgery. Typical complications in pancreatic
surgery are ﬁstulas, hemorrhages and, delayed gastric empty-
ing [29–31]. Clavien-Dindo classiﬁed overall postoperative
complicationsoccurred in51%of thepatients,which is slightly
more than the complication rate of 33–35% presented in a
recent systematic review [14], but similar to the overall com-
plication rates in pancreatic surgery. Postoperative mortality
was 3%, which is acceptable and similar to the percentages
reported in the systematic review (3.7% for open approach
and 0% for laparoscopic approach) [14]. Eighty-nine percent
of the patients who underwent curative surgery had a full
recovery. The recurrence rate (8%) was comparable to the
previously reported 7.2% [14]. Of note, current guidelines
suggest enucleation of sporadic small insulinomas (<2 cm),
if structural integrity of the pancreatic duct can be main-
tained [32]. Laparoscopic enucleation is currently considered
feasible even in challenging locations, such as the posterior
surface of the pancreatic neck [33, 34]. The complication risk
associated with enucleations is comparable or even higher
than with distal resections and PDs [35, 36]. For MEN1
patients, distal or subtotal pancreatectomy must be consid-
ered in multifocal disease, when other pancreatic NENs are
present, and in cases with potentially malignant disease.
A major strength of this study is the nationwide data
including all insulinomas diagnosed in Finland over three
decades. In contrast to many previous studies, we also
included inoperable cases, which constituted 6%of the cohort.
Collecting nationwide data enabled us to assess the incidence,
as well as the evolving methods of diagnostics and treatment
of insulinomas, in an unselected cohort of patients.
There are, however, some limitations to this study. Due to
the retrospective, register-based design of the study, there
was incompleteness in the data, regarding, e.g., the clinical
picture and the response to the medical treatment of insuli-
nomas. As the search for insulinomas was carried out on
patient and pathology registries and thus depends on correct
enrolling of the diagnoses, we may not have found all the
insulinomas, especially from the earlier years of the study
period. To minimize the loss of cases, a comprehensive
search was performed on three separate databases, and all
the potential cases found were reviewed. Another limitation
is the short follow-up, as patients with a benign insulinoma
are followed up at the University Hospitals only for a short
time after a successful operation. In case of a possible relapse
or disease progression, however, an insulinoma patient
would most likely have ended up at one of the ﬁve Finnish
University Hospitals with a new referral, and the relapse/pro-
gression would have been registered in our study. Thirdly, as
patient record data from primary health care was not avail-
able, we could not distinguish the health care system delay
(time from the ﬁrst consultation of health care providers to
the diagnosis) from the total diagnostic delay (from the onset
of symptoms) calculated in this study.
5. Conclusions
The incidence of insulinomas has increased during the past
three decades. The diagnostic delay has remained unchanged
since the 1980s, despite improved imaging. To shorten the
diagnostic delay, clinicians should be informed to consider
the possibility of hypoglycemia and insulinoma, when symp-
tomatic attacks are investigated in any health care unit.
Developing the surgical treatment is another major target
in the management of insulinomas, to lower the overall com-
plication rate, while ensuring the high cure rate.
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